Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

Blood Adv. 2023 Feb 28;7(4):644-648. doi: 10.1182/bloodadvances.2022007625.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents*
  • B-Cell Maturation Antigen
  • Humans
  • Immunotherapy, Adoptive
  • Multiple Myeloma*
  • Neoplasms, Plasma Cell*

Substances

  • B-Cell Maturation Antigen
  • Antineoplastic Agents